Tangshan Jidong Cement Co.,Ltd. (SHE:000401)

Intercept Pharmaceuticals Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Operating Revenue	25,708	25,146	28,105	34,454	36,174	35,181
Other Revenue	140.21	140.21	130.24	89.89	163.93	298.5
Revenue	25,849	25,287	28,235	34,544	36,338	35,480
Revenue Growth (YoY)	-2.06%	-10.44%	-18.26%	-4.94%	2.42%	2.82%
Cost of Revenue	21,755	21,598	26,113	28,843	27,986	25,330
Gross Profit	4,094	3,689	2,122	5,701	8,352	10,150
Selling, General & Admin	3,469	3,389	3,124	3,278	3,165	2,978
Research & Development	125.99	128.84	126.22	112.93	99.68	97.19
Other Operating Expenses	364.8	366.56	284.82	259.47	-37.96	-27.88
Operating Expenses	4,019	3,946	3,591	3,679	3,222	3,062
Operating Income	75.04	-257.43	-1,469	2,022	5,129	7,087
Interest Expense	-616.76	-642.72	-695.13	-744.18	-750.03	-976.33
Interest & Investment Income	218.54	219.45	247.28	227.43	566.15	537.56
Currency Exchange Gain (Loss)	-1.51	-1.51	-19.77	-	-	-
Other Non Operating Income (Expenses)	-17.42	-24.37	-7.97	57.73	291.33	-62.16
EBT Excluding Unusual Items	-342.1	-706.58	-1,944	1,563	5,237	6,586
Impairment of Goodwill	-14.3	-14.3	-	-	-	-
Gain (Loss) on Sale of Investments	2.06	-	-	-	-	-
Gain (Loss) on Sale of Assets	22.22	21.3	-23.02	20.31	14.78	1.14
Asset Writedown	-248.85	-248.85	-116.74	-25.7	-96	-39.52
Other Unusual Items	52.21	52.21	219.18	263.88	154.58	204.73
Pretax Income	-528.76	-896.22	-1,865	1,822	5,310	6,753
Income Tax Expense	339.27	239.62	-143.17	414.89	1,128	1,569
Earnings From Continuing Operations	-868.03	-1,136	-1,722	1,407	4,182	5,184
Minority Interest in Earnings	94.07	144.82	239.32	-49.19	-1,372	-2,334
Net Income	-773.96	-991.02	-1,482	1,358	2,810	2,850
Net Income to Common	-773.96	-991.02	-1,482	1,358	2,810	2,850
Net Income Growth	-	-	-	-51.69%	-1.40%	5.53%
Shares Outstanding (Basic)	2,662	2,657	2,676	2,647	1,589	1,451
Shares Outstanding (Diluted)	2,662	2,657	2,676	2,683	1,726	1,463
Shares Change (YoY)	-0.31%	-0.70%	-0.28%	55.44%	17.98%	0.39%
EPS (Basic)	-0.29	-0.37	-0.55	0.51	1.77	1.96
EPS (Diluted)	-0.29	-0.37	-0.55	0.51	1.63	1.95
EPS Growth	-	-	-	-68.92%	-16.43%	5.13%
Free Cash Flow	2,146	1,502	1,013	-212.55	3,909	6,395
Free Cash Flow Per Share	0.81	0.56	0.38	-0.08	2.27	4.37
Dividend Per Share	0.100	0.100	-	0.150	0.750	0.500
Dividend Growth	-	-	-	-80.00%	50.00%	-
Gross Margin	15.84%	14.59%	7.52%	16.50%	22.98%	28.61%
Operating Margin	0.29%	-1.02%	-5.20%	5.85%	14.12%	19.98%
Profit Margin	-2.99%	-3.92%	-5.25%	3.93%	7.73%	8.03%
Free Cash Flow Margin	8.30%	5.94%	3.59%	-0.61%	10.76%	18.02%
EBITDA	3,567	3,241	2,055	5,393	8,256	10,151
EBITDA Margin	13.80%	12.82%	7.28%	15.61%	22.72%	28.61%
D&A For EBITDA	3,492	3,499	3,524	3,371	3,127	3,064
EBIT	75.04	-257.43	-1,469	2,022	5,129	7,087
EBIT Margin	0.29%	-1.02%	-5.20%	5.85%	14.12%	19.98%
Effective Tax Rate	-	-	-	22.77%	21.25%	23.24%
Revenue as Reported	25,849	25,287	28,235	34,544	36,338	35,480
Advertising Expenses	-	6.83	7.69	11.95	13.62	10.62

Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.